TheraRadar
← Back
Data updated: Jun 28, 2026

SOLIS PHARMS

Generics

SOLIS PHARMS is a generic drug manufacturer focused on Dermatology.

1979
Since
5
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

SOLIS PHARMS's Key Drugs

SOLIS PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SOLIS PHARMS's Recent FDA Approvals

New NDA/BLA approvals for SOLIS PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SOLIS PHARMS's Therapeutic Areas

SOLIS PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 100%
1 drugs

SOLIS PHARMS's Top Competitors

SOLIS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SOLIS PHARMS Pipeline Snapshot

Active clinical trials for SOLIS PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling